How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,257 results for

Emergency Medicine Treatment and Labor Act

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Public health guidance on active case finding of communicable diseases in prison settings

. Evidence base on effectiveness of active case finding for TB in prison settings 20 Table 8. Evidence base on cost-effectiveness of active case finding for TB in prison settings 22 SCIENTIFIC ADVICE Public health guidance on active case finding of communicable diseases in prison settings v Abbreviations AGREE Appraisal of guidelines for research and evaluation cART Combined antiretroviral therapy CXR Chest x-ray DAA Direct-acting antivirals EEA European Economic Area EMCDDA European Monitoring Centre (...) for Drugs and Drug Addiction GRADE Grading of recommendations assessment, development and evaluation HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IGRA Interferon gamma release assay LTBI Latent tuberculosis infection MSM Men who have sex with men PRISMA Preferred reporting items for systematic reviews and meta-analyses PWID People who inject drugs STI Sexually transmitted infection TasP Treatment as prevention TB Tuberculosis TST Tuberculin skin test UNODC United Nations

2018 European Centre for Disease Prevention and Control - Public Health Guidance

282. Nifedipine

these patients' newborn babies. Threatened Preterm Labor Drug: Nifedipine Drug: Atosiban Phase 3 Study Type: Interventional Study Design: Allocation 2011 19. The efficacy of tamsulosin vs. nifedipine for the medical expulsive therapy of distal ureteric stones: A randomised clinical trial. 26558112 2015 11 11 2015 11 11 2017 02 20 2090-598X 11 4 2013 Dec Arab journal of urology Arab J Urol The efficacy of tamsulosin vs. nifedipine for the medical expulsive therapy of distal ureteric stones: A randomised (...) professional before volunteering for a study. Study Record Detail Nifedipine or Nifedipine Plus (...) View Purpose Tocolytic agents are used for the treatment of preterm labor. It is unclear whether combination treatments of two tocolytic agents are more effective in stopping preterm labor compared to one. Therefore, the investigators propose a comparative effective trial of nifedipine plus indomethacin vs. nifedipine alone for the treatment of preterm labor Preterm Labor Drug: Nifedipine Drug

2018 Trip Latest and Greatest

283. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

regression and cardiovascular risk reduction with antihypertensive treatment3045 5.7 When to refer a patient with hypertension for hospital-based care3046 6 Genetics and hypertension3047 7 Treatment of hypertension3048 7.1 Beneficial effects of blood pressure-lowering therapy in hypertension3048 7.2. When to initiate antihypertensive treatment3048 7.2.1 Recommendations in previous guidelines3048 7.2.2 Drug treatment for patients with grade 1 hypertension at low–moderate cardiovascular risk3048 7.2.3 (...) and diastolic blood pressure treatment targets3052 7.3.2 Blood pressure targets in specific subgroups of hypertensive patients3052 7.4 Treatment of hypertension3054 7.4.1 Lifestyle changes3054 7.4.2 Dietary sodium restriction3054 7.4.3 Moderation of alcohol consumption3055 7.4.4 Other dietary changes3055 7.4.5 Weight reduction3055 7.4.6 Regular physical activity3056 7.4.7 Smoking cessation3056 7.5. Pharmacological therapy for hypertension3056 7.5.1 Drugs for the treatment of hypertension3056 7.5.2

2018 European Society of Cardiology

284. Pneumonia induced by benzodiazepines

mongering Medical checkups create “patients” and shorten their lifespan by “treatment” Adverse Reactions Pneumonia induced by benzodiazepines Evidence shows causal relations CONTENTS (August 2018, Vol. 4, No. 11 ) 16 17 20 24 Volume 4 Page 16 · MED CHECK - TIP August 2018/ Vol.4 No.11 What we learned from epidemiological studies on drug-induced pneumonia It is well known that corticosteroids and cytotoxic anticancer agents cause infections. The labels of non- steroidal anti-inflammatory drugs (NSAIDs (...) effect or poor tolerability with other oral lipid lowering drugs is observed" [1-4]. For HoFH, drug therapy with statins or statins + ezetimibe (Zetia®) or removal of serum LDL-cholesterol (apheresis) has traditionally been performed [5-7]. However, the evidence basis of these treatments has been unknown so far, because randomized controlled A new cholesterol lowering agent: lomitapide is highly toxic Fat accumulates in the liver and small intestine Translated from Med Check-TIP in Japanese Jul 2018

2018 Med Check - The Informed Prescriber

285. The Foyer model for homeless youth: a systematic mapping review

included in the studies, most of whom were current of former residents of foyers. These young people had a similar pattern of support needs (e.g., being homeless for longer than one year, low ed- ucational achievements, illicit drug use, mental health problems, and rudimentary life skills). All the foyers in the included studies offered a similar package of support services (i.e., housing, education assistance and training, job seeking and life skills). The included studies encompassed different (...) . The authors would like to thank Lien Nguyen, research librarian, for help with develop- ing the search strategy and running the searches in the major databases. Signe Flottorp Acting dept. director Rigmor C Berg Head of unit Jose F. Meneses-Echavez Project leader 14 6BBackground Background Despite The United Nations Universal Declaration of Human Rights (Article 25) stating that everyone has a right to housing, homelessness is a well-documented problem around the world. To realize this right

2018 Norwegian Institute of Public Health

286. Do general health checks prolong lifespan?

and technology, and they were introduced as pharmaceuticals. Although novel drugs such as antihypertensive agents have "action to lower blood pressure”, the effect of prolonging the life span has not been proven by RCT except for a case of serious hypertension. Therefore, if RCT proved that a certain disease such as heart disease or stroke is reduced by the substance, it is accepted as a medicine. Cholesterol lowering agents and hypoglycemic agents are the other examples. Moreover, deregulation was made (...) is precisely elucidated, many receptors and their ligands (substances acting on receptors) are discovered, and numerous potential new drugs are developed. Since 2000, many clinical practice guidelines have been published in Japan as well. They are claimed to Who benefits from the guidelines? Translated from the Editorial in the issue 75 (Jan. 2018) as the introduction of the series: Critical appraisal of the Japanese “Practice Guidelines” have been created in accordance with the Evidence-Based Medicine

2018 Med Check - The Informed Prescriber

287. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

the safety and efficacy of switching to B/F/TAF vs continuing on boosted ATV or DRV plus either FTC/TDF or ABC/3TC B/F/TAF 50/200/25-mg tablet (EN1503B2, EN1504B1, EN1601B2, EN1602B2, EN1604B2, EN1606B2, EN1608B1, EN1609B1) 577 Current ARV drug regimen consisting of RTV- or COBI-boosted ATV or DRV plus either FTC/TDF or ABC/3TC administered orally once daily with food. Investigators provided a prescription for the ARV treatment, and subjects were responsible for obtaining the medication GS-US-380-1991 (...) substance: Bictegravir / Emtricitabine / Tenofovir Alafenamide International Non-proprietary Name/Common Name: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pharmaco-therapeutic group (ATC Code): Direct acting antivirals, antivirals for treatment of HIV infections, combinations (J05AR) Therapeutic indication(s): Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class

2018 European Medicines Agency - EPARs

288. Supporting people in social housing gain and maintain employment

” OR “Indigenous housing” OR “social housing” OR “public housing” OR “community housing” OR “supported housing” OR “temporary” OR “registered social” AND 2. “Employment” OR “activation” OR “work” OR “welfare” OR “labor” OR “labour” OR “voucher” OR “rental assistance” AND 3. “assessment” OR “review” OR “evaluation” Additional searches included variants of “client focus”, “client centred” and “case management” as search items. Searches of the following databases and institutional websites generated a list of 826 (...) , there is by no means a consensus that public housing is associated with lock-in effects, or voluntary withdrawal from the labour market or under employment. Feeny et al. 26 argue that public housing is an in-kind benefit, supplied as a one-off bundle, and that this weakens the argument that it acts as a work disincentive. They also reviewed a range of studies that produced only weak evidence that receipt of housing assistance reduces earnings and/or labour market participation. They found evidence

2018 Sax Institute Evidence Check

289. Review of effective strategies to promote breastfeeding

INSTITUTE Executive summary Purpose of the Evidence Check Babies who are not breastfed, and women who don’t breastfeed, are at an increased chance of many health risks in both the short and long term, including in high-income countries such as Australia. 1, 2 Studies in countries such as the US, Britain and Australia have also shown that the economic and health treatment costs of prevailing low rates of breastfeeding are high. Globally, interventions to support breastfeeding are among the most effective (...) in Organisation for Economic Co-operation and Development (OECD) countries. Most such studies investigate the cost consequences of interventions to increase human milk feeding or breastfeeding among socially or medically at-risk infants. In Britain, recent studies support the cost-effectiveness of proactive and reactive calls to REVIEW OF STRATEGIES TO PROMOTE BREASTFEEDING | SAX INSTITUTE 9 mothers living in disadvantaged areas, and for enhanced lactation support in in neonatal intensive care units (NICUs

2018 Sax Institute Evidence Check

290. Glibenclamide (Amglidia) - Diabetes Mellitus

-proprietary name: glibenclamide Procedure No. EMEA/H/C/004379/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. CHMP assessment report EMA/153558/2018 Page 2/60 Administrative information Name of the medicinal product: Amglidia Applicant: Ammtek 15, rue Beranger 75003 Paris FRANCE Active substance: GLIBENCLAMIDE International Nonproprietary Name: glibenclamide Pharmaco-therapeutic group (ATC Code): BLOOD GLUCOSE LOWERING DRUGS, EXCL (...) . INSULINS, Sulfonylureas (A10BB01) Therapeutic indication: Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the ß-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus. Pharmaceutical form Oral suspension Strengths: 0.6 mg/ml and 6 mg/ml Route of administration: Oral use Packaging

2018 European Medicines Agency - EPARs

291. Treating Opioid Use Disorder During Pregnancy: Guideline Supplement

brief intervention and support and be encouraged continue to engage in treatment. 6,30 Depending on the substance (e.g., tobacco, alcohol, pharmaceutical or illegal drugs) and diagnosis (e.g., high-risk use, substance use disorder), treatment for this group of patients may involve pharmacotherapy, and/or appropriate referrals to specialist care as required or requested. 6,28 All patients of childbearing capacity starting OAT should be offered screening for pregnancy at intake, and contraceptive (...) and buprenorphine/naloxone for the treatment of opioid use disorder in pregnancy. 8,9,32-34 It is important to note that, unless clinically indicated, transitioning between methadone, buprenorphine/ naloxone, and slow-release oral morphine is NOT advisable for patients who are stable on one of these agents during pregnancy and postpartum; the process of reducing and titrating medication dosage during transition may result in the re-emergence of withdrawal symptoms and increased risk of relapse. Research has

2018 British Columbia Perinatal Health Program

292. Velmanase alfa (Lamzede) - alpha-Mannosidosis

is available, and the older less severe patients are managed with supportive care including symptom management, medical and surgical treatment of complications (e.g. infections, skeletal deformities), and physical therapy. About the product Lamzede is a recombinant human alpha mannosidase developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis. The objective of treatment with velmanase alfa is to administer the deficient enzyme into the blood stream, from where (...) , diagnosis and prognosis 9 2.1.5. Management 10 2.2. Quality aspects 12 2.2.1. Introduction 12 2.2.2. Active Substance 12 2.2.3. Finished Medicinal Product 17 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 19 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 20 2.3. Non-clinical aspects 20 2.3.1. Introduction 20 2.3.2. Pharmacology 20 2.3.3. Pharmacokinetics 26 2.3.4. Toxicology 27 2.3.5. Ecotoxicity/environmental risk assessment 33 2.3.6. Discussion on non

2018 European Medicines Agency - EPARs

293. Sodium zirconium cyclosilicate (Lokelma) - Hyperkalemia

presentation, diagnosis 8 2.1.4. Management 8 2.2. Quality aspects 9 2.2.1. Introduction 9 2.2.2. Active Substance 9 2.2.3. Finished Medicinal Product 12 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 14 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects 15 2.2.6. Recommendations for future quality development 15 2.3. Non-clinical aspects 15 2.3.1. Introduction 15 2.3.2. Pharmacology 15 2.3.3. Pharmacokinetics 17 2.3.4. Toxicology 18 2.3.5. Ecotoxicity (...) deficiency), pharmacologic (e.g. treatment with angiotensin-converting enzyme inhibitors [ACEs], angiotensin-receptor blockers [ARBs], mineralocorticoid receptor antagonists) or, most commonly, due to reduced kidney function. Often, the cause is multifactorial (e.g. reduced kidney function combined with drug treatment such as ACEs or ARBs). Increased extracellular potassium levels result in depolarization of the membrane potential of cells. This depolarization opens some voltage gated sodium EMA/93250

2018 European Medicines Agency - EPARs

294. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

contraindications to metformin. Subsequently, if the A1C target is not achieved after approximately 3 months, therapy should be augmented to a 2-drug combination followed by the addition of other AHAs approximately every 3 months if the A1C goal is not achieved. Despite the availability of a broad array of AHAs, only approximately half of patients with T2DM achieve glycaemic control per treatment guidelines. Furthermore, while new classes of AHA medications have been introduced over the last decade (...) 2.1.1. Disease or condition 9 2.1.2. Epidemiology 9 2.1.3. Clinical presentation 9 2.1.4. Management 10 2.2. Quality aspects 12 2.2.1. Introduction 12 2.2.2. Active Substance - ertugliflozin 12 2.2.3. Active Substance - sitagliptin 15 2.2.4. Finished Medicinal Product 16 2.2.5. Discussion on chemical, pharmaceutical and biological aspects 19 2.2.6. Conclusions on the chemical, pharmaceutical and biological aspects 19 2.2.7. Recommendation(s) for future quality development 19 2.3. Non-clinical

2018 European Medicines Agency - EPARs

295. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

for the Study of Diabetes (EASD) recommend a stepwise and individualized treatment approach to T2DM. These guidelines recommend metformin as the optimal first-line anti-hyperglycaemic agent (AHA), unless the patient has contraindications to metformin. Subsequently, if the A1C target is not achieved after approximately 3 months, therapy should be augmented to a 2-drug combination followed by the addition of other AHAs approximately every 3 months if the A1C goal is not achieved. Despite the availability (...) 9 2.1.1. Disease or condition 9 2.1.2. Epidemiology 9 2.1.3. Clinical presentation 9 2.1.4. Management 10 2.2. Quality aspects 12 2.2.1. Introduction 12 2.2.2. Active Substance - ertugliflozin 12 2.2.3. Active Substance - Metformin hydrochloride 15 2.2.4. Finished Medicinal Product 16 2.2.5. Discussion on chemical, pharmaceutical and biological aspects 19 2.2.6. Conclusions on the chemical, pharmaceutical and biological aspects 20 2.2.7. Recommendation(s) for future quality development 20 2.3

2018 European Medicines Agency - EPARs

296. Organisation of mental health care for adults in Belgium

and behaviours 60 3.2 MENTAL HEALTH CARE SERVICE USE 61 3.2.1 Use of medication 61 3.2.2 Mental health care services use among adults at risk for depression 63 4 CONCLUSION 64 5 KEY MESSAGES 64 6 REFERENCES 65 CHAPTER 03 COMPARABILITY OF ESEMED AND HIS 66 KCE Report 318 Organisation Mental Health Care adults Belgium 3 AUTHORS: DETOLLENAERE J 1 , BRUFFAERTS R 2 , GISLE L 3 , MISTIAEN P 1 66 1 INTRODUCTION 66 2 METHODS 66 2.1 THE EUROPEAN STUDY OF THE EPIDEMIOLOGY OF MENTAL DISORDERS (ESEMED) 66 2.2 (...) AT HOME 146 6.6 COORDINATION AND ADDICTION NETWORKS 146 6.6.1 Networks of assistance and specialised care on addictions 146 6.6.2 Flemish expertise centre on alcohol and other drugs 147 6.6.3 Eurotox 147 6.7 REGIONAL COORDINATION IN MH 147 6.7.1 The centre of reference for mental health 147 6.7.2 Mental Health Focal Point 148 6.7.3 French-speaking Brussels league for mental health 148 7 TRANSFER OF COMPETENCES (6 TH STATE REFORM) 149 8 DISCUSSION 150 8.1 PRECAUTIONS ABOUT THE COLLECTED DATA 150 8.2

2019 Belgian Health Care Knowledge Centre

297. Asylum seekers in Belgium: options for a more equitable access to health care. A stakeholder consultation

patient confidentiality 43 5.2.8 Lack of appropriate health information for asylum seekers 43 5.3 PROBLEMS AT THE MICRO-LEVEL 43 5.3.1 Inequity in access 43 5.3.2 Inequity in treatment 45 5.3.3 Inequity in outcomes 46 5.4 SPECIFIC PROBLEMS FOR HEALTH CARE WITH UNACCOMPANIED MINORS 47 5.4.1 Lack of coverage through insurance funds for unaccompanied minors 47 5.4.2 Difficulties to comply with the conditions to access the compulsory health insurance 47 5.4.3 Shortage of guardians 47 KCE Report 319 Asylum (...) seekers in Belgium 3 5.4 OTHER ISSUES 47 6 OPTIONS TO IMPROVE EQUITABLE ACCESS TO HEALTH CARE FOR ASYLUM SEEKERS: RESULTS OF THE STAKEHOLDER CONSULTATION 50 6.1 FUNDAMENTAL TRANSVERSAL PRINCIPLES TO IMPROVE EQUITABLE ACCESS 50 6.2 DISTRIBUTION OF FUNDING OF HEALTH CARE FOR ASYLUM SEEKERS 51 6.2.1 Option 1: Sickness funds acts as distributor of funding – integration of asylum seekers in compulsory Belgian health care insurance 51 6.2.2 Option 2: Fedasil acts as distributor of funding 61 6.2.3 Option 3

2019 Belgian Health Care Knowledge Centre

298. Diagnosis and management of gonorrhoea and syphilis

for gonorrhoea in women 78 Diagnosis of gonorrhoea: Good practice statements 79 3.3 TREATMENT OF GONORRHOEA: INFORMATION AND ADVICE FOR THE PATIENT 79 Recommendations from international guidelines 79 Recommendations regarding information and advice for the patient 80 3.4 TREATMENT OF GONORRHOEA: TIMING OF INITIATION OF THERAPY 81 Recommendations from international guidelines 81 Recommendations regarding testing and surveillance for resistance 82 Recommendation regarding initiation of therapy 82 3.5 TREATMENT (...) diagnosis 141 Choice of tests for syphilis diagnosis: Good practice statements 142 3.14 TREATMENT OF SYPHILIS: INFORMATION AND ADVICE FOR THE PATIENT 142 Recommendations from international guidelines 142 Recommendations regarding syphilis information and advice for the patient 143 3.15 TREATMENT OF SYPHILIS: INITIATION OF THERAPY AND REFERRAL TO SECOND LINE 143 Recommendation regarding initiation of syphilis therapy 143 Recognising syphilis clinical symptoms: Good practice statements 144 When to refer

2019 Belgian Health Care Knowledge Centre

299. Managing health and wellbeing in the workplace

to confirm the availability of systematic review (SR) evidence, the recency of analysis, and the adequacy of coverage across the specified research questions. Since the evidence coverage was deemed adequate, we proceeded with a more robust review using a typical selection of electronic databases. Search terms were selected consistent the US National Library Medical Subject Headings (MeSH®) Thesaurus (with modifications as required for specific databases). Grey literature searches were also undertaken (...) Assessment) and more emergent for the recent or more complex components (for example, systems approaches). We have distilled a model (Workplace Wellness 3.0) which is designed to capture these, whilst also showing the current status of the underpinning evidence. There is strong (definitive) evidence that lifestyle management interventions as part of workplace wellness programs can reduce risk factors, such as smoking, and increase healthy behaviours, such as exercise and healthy eating; these effects

2018 Sax Institute Evidence Check

300. Management of Decompensated Cirrhosis

insertion. Thus, the search for alternative treatments is warranted. Medical treatments. Therapies aimed at improving circulatory and renal function have been proposed. The a1-adrenergic agonist midodrine has been shown to improve systemic and renal haemodynamics in patients with cirrhosis and uncom- plicated ascites. 115 In a small RCT comparing the addition of midodrine (7.5mgt.i.d) to diuretic treatment with diuretic treatment alone in patients with refractory or recurrent ascites for six months (...) Pleasecitethisarticleinpressas:TheEuropeanAssociationfortheStudyof theLiver. EASLClinicalPracticeGuidelinesforthemanagementof patientswithdecompensatedcirrhosis.J Hepatol (2018), https://doi.org/10.1016/j.jhep.2018.03.024alsoplayarole,especiallyinthemostadvancedstagesofcirrho- sis. 5 Portal hypertension also contributes 30 by acting as a com- partmentalising factor of the expanded extracellular ?uid volume. The occurrence of ascites impairs patient working and social life, often leads to hospitalisation, requires chronic treatment and is a direct cause

2018 European Association for the Study of the Liver

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>